



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
PTO FORM 1449		APPLICANT Jose L. BOYER, et al.	
		FILING DATE 30 March 2004	GROUP 1623

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL	1.	3,321,463	05-23-67	Moffatt, et al.	260	211.5	03-17-65
	2.						
	3.						
	4.						
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	5.						
	6.						
	7.						
	8.						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
PL	9.	Moffatt, et al., "Nucleoside polyphosphates...", Journal of the American Chemical Society (1958), 80, 3756-61.					
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						
	16.						
	17.						

Patricia L. Lee 9-29-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small>		ATTORNEY DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
PTO FORM 1449		APPLICANT BOYER, et al.	
		FILING DATE March 30, 2004	GROUP Not yet Assigned

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL		US 4,621,076	11/04/86				
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES	NO	
PL	1.	WO 99/61012	12/02/99	PCT			
↓	2.	WO 89/04321	05/18/89	PCT			
↓	3.	GB 1407903	10/01/75	United Kingdom			
PL	4.	International Search Report PCT/US01/41818	03/11/02	PCT			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
PL	5.	Hamilton, A. et al., "Design of Substrate-Site-Directed Inhibitors of Adenylate Kinase and Hexokinase. Effect of Substrate Substituents on Affinity for the Adenine Nucleotide Sites", <i>J. Med. Chem.</i> , 19 :1371-1377 (1976)					
↑	6.	Hiratsuka T., "Affinity Labeling of the Myosin ATPase with Ribose-Modified Fluorescent Nucleotides and Vanadate", <i>J. Biochem.</i> , 96 :147-154 (1984)					
↑	7.	Martin, P. et al., "Structure-Activity Studies of Analogs of β , γ -Methylene-ATP at P_{2x} -Purinoceptors in the Rabbit Ear Central Artery", <i>Drug Development Research</i> , 36 : 153-165 (1995)					
↑	8.	Metzker, M. et al., "Termination of DNA synthesis by novel 3'-modified-deoxyribonucleoside 5'-triphosphate", <i>Nucleic Acids Research</i> , 22 :4259-4267 (1994)					
↑	9.	Pellicano, H. et al., "Study of the substrate-binding properties of bovine liver adenosine kinase and inhibition by fluorescent nucleoside analogues", <i>Eur. J. Biochem.</i> , 248 :930-937 (1997)					
↓	10.	Richard, J. and Frey, P.A., "Stereochemical Course of Thiophosphoryl Group Transfer Catalyzed by Adenylate Kinase", <i>J. Am. Chem. Soc.</i> , 100 :7757-7758 (1978)					
PL	11.	Sekine, M. et al., "New Type of Chemical Oxidative Phosphorylation: Activation of Phosphonate Function by Use of Triisopropylbenzenesulfonyl Chloride", <i>Tetrahedron Letters</i> , 1145-1148 (1997)					


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent 29
JUL 30 2005

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		ATTORNEY DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
PTO FORM 1449		APPLICANT BOYER, et al.	
		FILING DATE March 30, 2004	GROUP Not yet Assigned

	12.	Zatorski, A. et al., "Chemical Synthesis of Benzamide Adenine Dinucleotide: Inhibition of Inosine Monophosphate Dehydrogenase (Types I and II)", <i>Journal of Medicinal Chemistry, American Chemical Society</i> , 39:2422-2426 (1996)
	EXAMINER 	DATE CONSIDERED 9-29-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <small>(See several sheets if necessary)</small> PTO FORM 1449 <small>JUL 26 2006</small> 		ATTY. DOCKET NO. 03678.0064.CPUS02	APPLICATION NO. 10/814,007
		APPLICANT Jose L. BOYER, et al.	
		FILING DATE 30 March 2004	GROUP

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL	1.	• 5,049,550	09/17/91	Zamecnik	514	47	11/21/88
	2.	• 5,654,285	08/05/97	Ingall, et al.	514	47	06/06/95
	3.	• 5,681,823	10/28/97	Kim, et al.	514	47	05/02/96
	4.	• 5,721,219	02/24/98	Ingall, et al.	514	47	08/09/95
	5.	• 5,747,496	05/05/98	Cox, et al.	514	258	07/04/96
	6.	• 5,814,609	09/29/98	Markland, Jr. et al.	514	12	11-08-96
	7.	• 5,837,861	11/17/98	Pendergast, et al.	536	25.6	02/10/97
	8.	• 5,900,407	05/04/99	Yerxa, et al.	514	47	02/06/97
	9.	• 5,955,447	09/21/99	Ingall, et al.	514	47	08/28/97
	10.	• 6,166,022	12/26/00	Brown, et al.	514	258	07/15/98
	11.	• 6,323,187	11/27/01	Yerxa, et al.	514	51	05/21/99
PL	12.	6,348,589	02/19/02	Pendergast, et al.	536	25.6	02/06/98
PL	13.	6,596,725	07/22/03	Peterson, et al.	514	25.6	01/30/01

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PL	14.	• WO 92/ 01673	07/11/91	PCT			X	
	15.	• WO 92/17488	10/15/92	PCT			X	
	16.	• WO 94/08593	28/04/94	PCT			X	
	17.	• WO 94/18216	08/18/94	PCT			X	
	18.	• WO 97/03084	01/30/97	PCT			X	
	19.	• WO 97/29456	21/08/97	PCT			X	
	20.	• WO 98/03182	29/01/98	PCT			X	
	21.	• WO 98/28300	07/02/99	PCT			X	
PL	22.	• WO 98/34593	13/08/98	PCT			X	
PL	23.	• WO 99/01138	14/01/99	PCT			X	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



9-29-05

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO.	APPLICATION NO.
PTO FORM 1449		03678.0064.CPUS02	10/814,007
APPLICANT		Jose L. BOYER, et al.	
FILING DATE		GROUP	
30 March 2004			

PL	24. *	WO 99/32085	01/07/99	PCT		X	
	25. *	WO 00/33080	06/08/00	PCT		X	
	26. *	WO 00/34283	06/15/00	PCT		X	
	27. *	WO 00/39145	06/07/00	PCT		X	
	28. *	WO 00/50024	31/08/00	PCT		X	
	29. *	WO 01/19826	03/22/01	PCT		X	
✓	30.	WO 01/39781	07/06/01	PCT		X	
PL	31. *	WO 01/36421	05/25/01	PCT		X	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
PL	32. *	Alessi, D. et al., "Synthesis and Properties of a Conformationally Restricted Spin-Labeled Analog of ATP and Its Interaction with Myosin and Skeletal Muscle" <i>Biochemistry</i> (1992), 31(34), 8043-54.					
	33. *	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of Death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients," <i>Br. Med. J.</i> 308: 81-106 (1994)					
	34. *	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-II : Maintenance of Vascular graft or arterial patency by antiplatelet therapy," <i>Br. Med. J.</i> 308: 159-168 (1994)					
	35. *	Antman, E. for The TIMI 9a investigators, "Hirudin in Acute Myocardial Infarction," <i>Circulation</i> , 90(4):1624-1630 (1994)					
	36. *	Bernat, A., et al., "Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat," <i>Thromb. Haemostas.</i> (1993) 70(5):812-816					
	37. *	Bujalowski, W. et al., "Structural Characteristics of the Nucleotide-Binding Site of <i>Escherichia coli</i> Primary Replicative Helicase DnaB Protein. Studies with Ribose and Base-Modified Fluorescent Nucleotide Analogs" <i>Biochemistry</i> (1994), 33(15), 4682-94.					
	38. *	Bush, L., et al., "Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries," <i>Circulation</i> 69(6):1161-1170, (1984)					
	39. *	Cardullo, R. A. et al., "Synthesis, Purification, and Characterization of 2,4,6-Trinitrophenyl-UDP-galactose: A Fluorescent Substrate for Galactosyltransferase" <i>Analytical Biochemistry</i> (1990), 188(2), 305-9.					
✓	40. *	Carvalho-Alves, P. et al., "Stoichiometric Photolabeling of Two Distinct Low and High Affinity Nucleotide Sites in Sarcoplasmic Reticulum ATPase" <i>Journal of Biological Chemistry</i> (1985), 260(7), 4282-7.					
PL	41. *	Chapal, J. et al., "Comparative effects of adenosine-5'-triphosphate and related analogs on insulin secretion from the rat pancreas" <i>Fundamental & Clinical Pharmacology</i> (1997), 11(6), 537-545.					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patricia Len 9-30-05

LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO.	APPLICATION NO.
PTO FORM 1449		03678.0064.CPUS02	10/814,007
		APPLICANT	
		Jose L. BOYER, et al.	
		FILING DATE	GROUP
		30 March 2004	

PL	42. *	Folts, J. et al., "Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Aspirin," <i>Circulation</i> 54(3):365-370 (1976)
	43. *	Frederick, L.G., et al., "The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Aspirin and Heparin in a Canine Model of Coronary Artery Thrombosis," <i>Circulation</i> 93(1):129-134 (1996)
	44. *	Geiger, J., et al., "Specific Impairment of Human Platelet P2Y ac ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel," <i>Arterioscler. Thromb. Vasc. Biol.</i> 19:2007-2011 (1999)
	45. *	Hass, W., et al., "A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke for High-Risk Patients," <i>N. Engl. J. Med.</i> , 321(8):501-507 (1989)
	46. *	Herbert, J.M. et al., Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits," <i>Arterioscl. Thromb.</i> (1993) 13(8):1171-1179
	47. *	Hiratsuka, Toshiaki, "Biological Activities and Spectroscopic Properties of Chromophoric and Fluorescent Analogs of Adenine Nucleoside and Nucleotides, 2',3'-O-(2,4,6-Trinitrocyclohexadienylidene) Adenosine Derivatives" <i>Biochimica et Biophysica Acta</i> (1982), 719(3), 509-17.
	48. *	Hiratsuka, Toshiaki, "Monitoring the Myosin ATPase Reaction Using a Sensitive Fluorescent Probe: Pyrene-Labeled ATP" <i>Biophysical Journal</i> (1997), 72(2, Pt. 1), 843-849.
	49. *	Hourani, et al., The Platelet ADP Receptors Meeting, La Thuile, Italy, March 29-31, 2000
	50. *	Humphries, R.G., et al., "Pharmacological profile of the novel P2T-Purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vitro," <i>Br. J. Pharmacol.</i> 115:1110-1116 (1995)
	51. *	Ikehara, M. et al., "III. Interaction Between Synthetic Adenosine Triphosphate Analogs and Actomyosin Systems" <i>Biochimica et Biophysica Acta</i> (1965), 100(2), 471-8.
	52. *	Ikehara, M. et al., "Unusual Rapid Cleavage of Terminal Phosphate Group of N6-Disubstituted Adenosine 5'-Triphosphate (ATP) by Divalent Cation" <i>Biochimica et Biophysica Acta</i> (1964), 85(3), 512-515.
	53. *	Ingall, A., et al., "Antagonists of the Platelet P2t Receptor: A Novel Approach to Antithrombotic Therapy," <i>J. Med. Chem.</i> 42: 213-220 (1999)
	54. *	Kim, et al., "Characterization of the Purinergic P ₂ Receptors in PC12 Cells," <i>Journal of Biological Chemistry</i> (1994), 269:6471-6477.
	55. *	Kwiatkowski, A. et al., "Mapping of the Adenosine 5'-Triphosphate Binding Site of Type II Calmodulin-Dependent Protein Kinase" <i>Biochemistry</i> (1987), 26(24), 7636-40.
	56. *	Lazarowski, E., et al., "Pharmacological selectivity of the cloned human P2u-purinoceptor: potent activation by diadenosine tetraphosphate," <i>Brit. J. Pharm.</i> 116:1619-1627 (1995)
PL	57. *	Lekstrom, J and William R. Bell, "Aspirin in the Prevention of Thrombosis," <i>Medicine</i> 70(3):161-178 (1991)
PL	58. *	Lowe, G. et al., "Evidence of a Dissociative S _N 1(P) Mechanism of Phosphoryl Transfer by Rabbit

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Peter Len 9-29-05

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO.	APPLICATION NO.
PTO FORM 1449		03678.0064.CPUS02	10/814,007
		APPLICANT	
		Jose L. BOYER, et al.	
		FLING DATE	GROUP
		30 March 2004	

<i>PL</i>		Muscle Pyruvate Kinase" <i>Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</i> (1972-1999) (1978), (12), 1622-30.
<i>PL</i>	59. *	Marian, M., "Acetyl Derivatives of Nucleoside 5'-Triphosphates. I." <i>Microchemical Journal</i> (1984), 29(2), 219-27.
	60. *	Mayer, I. et al., "Interaction of Fluorescent Adenine Nucleotide Derivatives with the ADP/ATP Carrier in Mitochondria. 1. Comparison of Various 3'-O-Ester Adenine Nucleotide Derivatives" <i>Biochemistry</i> (1984), 23(11), 2436-42.
	61. *	Mickelson, J.K., et al., "Antiplatelet Antibody [7E3 F(ab')2] Prevents Rethrombosis After Recombinant Tissue-Type Plasminogen Activator-Induced Coronary Artery Thrombolysis in a Canine Model." <i>Circulation</i> 81(2):617-627 (1990)
	62. *	Muratliev, M. et al., "Interaction of mitochondrial F ₁ -ATPase with trinitrophenyl derivatives of ATP. Photoaffinity labeling of binding sites with 2-azido-2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate" <i>European Journal of Biochemistry</i> (1995), 232(2), 578-85.
	63. *	Neuhaus., K. L. et al., "Safety Observations from the Piolet Phase of the Randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study," <i>Circulation</i> , 90(4): 1638-1642 (1994)
	64. *	Oliveira, C. R. G. et al., "Interaction of Spin-Labeled Nucleotides with Sarcoplasmic Reticulum Adenosinetriphosphatase" <i>Biochemistry</i> (1988), 27(16), 5923-7.
	65. *	Olivier, K., et al., "Acute Safety and Effects on Mucociliary Clearance of Aerosolized Uridine 5' -Triphosphate + Amiloride in Normal Human Adults," – <i>Am. J. Respir. Crit. Care Med.</i> 154:217-223 (1996)
	66. *	Quinn, M and Desmond J. Fitzgerald, "Ticlopidine and Clopidogrel," <i>Circulation</i> 100(15):1667-1672 (1999)
	67. *	Ray, S. et al., "Microenvironment at the Substrate Binding Subsite of the Active Site of UDPglucose 4-Epimerase from Kluyveromyces Fragilis Using a Fluorescent Analog of UMP" <i>Indian Journal of Biochemistry & Biophysics</i> (1992), 29(2), 209-13.
	68. *	Romson, J., et al., "Electrical Induction of Coronary Artery Thrombosis in the Ambulatory Canine: A model for IN VIVO Evaluation of Anti-Thrombotic Agents," <i>Thromb. Res.</i> 17:841-853 (1980)
	69. *	Seebregts, C. et al., "2',3'-O-(2,4,6-Trinitrophenyl)-8-Azido-adenosine Mono-, Di-, and Triphosphates as Photoaffinity Probes of the Ca ²⁺ -ATPase of Sarcoplasmic Reticulum. Regulatory/Superfluorescent Nucleotides Label the Catalytic Site with High Efficiency" <i>Journal of Biological Chemistry</i> (1989), 264(4), 2043-52.
	70. *	Shebuski, R., et al., "Acceleration of Recombinant Tissue-Type Plasminogen Activator-Induced Thrombolysis and Prevention of Reocclusion by the Combination of Heparin and the Arg-Gly-Asp-Containing Peptide Bitistatin in a Canine Model of Coronary Thrombosis," <i>Circulation</i> 82(1):169-177 (1990)
<i>PL</i>	71. *	Soslau, G. et al., "Aggregation of Human and Canine Platelets: Modulation by Purine Nucleotides" <i>Thrombosis Research</i> (1993), 72(2), 127-37.
<i>PL</i>	72. *	Thoenges D. et al., "Tight Binding of Bulky Fluorescent Derivatives of Adenosine to the Low Affinity E ₂ ATP Site Leads to Inhibition of Na ⁺ /K ⁺ -ATPase. Analysis of Structural Requirements of

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent Len - 9-29-05

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.	APPLICATION NO.
		03678.0064.CPUS02	10/814,007
		APPLICANT	
		Jose L. BOYER, et al.	
		FILING DATE	GROUP
		30 March 2004	

<i>PL</i>		Fluorescent ATP Derivatives with a Koshland-Nemethy-Filmer Model of Two Interacting ATP Sites" <i>Journal of Biological Chemistry</i> (1999 Jan 22), 274(4), 1971-8.
	73. *	Tschopp, J.F., et al., "Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time," <i>Coron. Artery Dis.</i> 4:809-817(1993)
	74. *	Vigne, P. et al., "Benzoyl ATP Is an Antagonist of Rat and Human P2Y ₁ Receptors and of Platelet Aggregation" <i>Biochemical and Biophysical Research Communications</i> (1999), 256(1), 94-97.
<i>✓</i>	75. *	Ward, D. et al., "Photoinactivation of Fluorescein Isothiocyanate-modified Na,K-ATPase by 2'(3')-O-(2,4,6-Trinitrophenyl)8-azidoadenosine 5'-Diphosphate. Abolition of E1 and E2 Partial Reactions by Sequential Block of High and Low Affinity Nucleotide Sites" <i>Journal of Biological Chemistry</i> (1998), 273(23), 14277-14284.
<i>PL</i>	76. *	Weber, M., et al., "Low-Dose Aspirin Versus Anticoagulants for Prevention of Coronary Graft Occlusion," <i>Am. J. Cardiol.</i> 66:1461-1468 (1990)

Patricia Lee 9-29-08

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.